HM Payson & Co’s 10x Genomics TXG Stock Holding History

HM Payson & Co’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-113	Closed	-$17K	–	1158
2021 Q4	$17K	Buy	113 +103	+1,030%	+$15.8K	﹤0.01%	792
2021 Q3	$1K	Hold	10	–	–	﹤0.01%	1063
2021 Q2	$2K	Sell	10 -234	-96%	-$42.3K	﹤0.01%	1017
2021 Q1	$44K	Hold	244	–	–	﹤0.01%	627
2020 Q4	$35K	Buy	244 +27	+12%	+$3.92K	﹤0.01%	674
2020 Q3	$27K	Buy	+217	New	+$22.8K	﹤0.01%	686

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HM Payson & Co's TXG Position: Q1 2022 in Review

HM Payson & Co sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 113 shares — an estimated $17K sold.

HM Payson & Co first reported a position in TXG in Q3 2020 and held it in 6 quarters. The position peaked at $44K in Q1 2021. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

HM Payson & Co reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
HM Payson & Co sold 113 10x Genomics shares in Q1 2022, an estimated $17K.
HM Payson & Co first reported a position in 10x Genomics in Q3 2020 and held it in 6 quarters.
HM Payson & Co's 10x Genomics position peaked at $44K in Q1 2021.
314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on HM Payson & Co's 13F filing for Q1 2022, filed 12 May 2022.